The Bamlanivimab+Etesevimab are anti-SARC-COVID-2 monoclonal antibodies which have received Emergency Use Authorization (EUA) from US FDA as well as conditional use approval from the MoHP, Department of Drug Administration (DDA)…
The post Protocol for Using Bamlanivimab + Etesevimab Anti-SARC-CoVID-2 Monoclonal Antibodies appeared first on Public Health Update.
http://dlvr.it/SC2r4p
